D81.1

Clinical Causes: Genetic mutations that affect the development and function of T and B lymphocytes, essential cells of the immune system. Inheritance patterns, typically autosomal recessive, meaning a child must inherit defective genes from both parents. Specific gene mutations may include mutations in the IL2RG gene, which accounts for X-linked SCID, or other genes involved in lymphocyte development such as JAK3, RAG1, RAG2, and others.

Key Symptoms: Recurrent and severe bacterial, viral, and fungal infections from early infancy. Persistent diarrhea and failure to thrive due to inability to fight intestinal infections. Skin infections, including bacterial abscesses and thrush. Pneumonia that is difficult to resolve and recurs frequently. Absence or very low levels of T and B cells in blood tests. Swollen lymph nodes or spleen may be absent or underdeveloped.

Diagnosis Path: Diagnosis of SCID with low T- and B-cell numbers involves a combination of clinical suspicion based on recurrent infections and laboratory testing. Key diagnostic steps include: - **Blood tests** to evaluate lymphocyte counts, focusing on T and B cell populations. - **Immunoglobulin levels** assessment, often revealing low or absent immunoglobulins. - **Genetic testing** to identify specific mutations responsible for the immune deficiency. - **Newborn screening** programs that measure T-cell receptor excision circles (TREC) levels, aiding early detection. - **Lymphocyte proliferation tests** to assess immune cell response to specific stimuli. Prompt diagnosis is critical to initiating treatment and improving chances of survival.

Treatment Protocols: Management of SCID with low T- and B-cell counts typically involves methods aimed at restoring the immune system or protecting the child from infections: - **Hematopoietic stem cell transplantation (HSCT):** This is the most effective treatment, offering a potential cure by replacing defective immune cells with healthy ones from a donor. - **Gene therapy:** Emerging treatments involve correcting specific genetic mutations in the patient's own cells. - **Immunoglobulin replacement therapy:** Regular infusions to provide necessary antibodies that the body cannot produce. - **Prophylactic antibiotics and antifungals:** To prevent infections in immunocompromised patients. - **Strict infection control measures:** Including avoiding exposure to infectious agents and maintaining good hygiene. Early intervention and a multidisciplinary approach are vital to improve survival rates and quality of life for individuals with SCID.